Limits...
Comparison of long-term survival and toxicity of cisplatin delivered weekly versus every three weeks concurrently with intensity-modulated radiotherapy in nasopharyngeal carcinoma.

Tao CJ, Lin L, Zhou GQ, Tang LL, Chen L, Mao YP, Zeng MS, Kang TB, Jia WH, Shao JY, Mai HQ, Lin AH, Ma J, Sun Y - PLoS ONE (2014)

Bottom Line: The clinical characteristics and treatment factors of the two groups were well-balanced.The median follow-up was 74 months (range, 6-123 months), and the 5-year overall survival, disease-free survival, locoregional relapse-free survival, and distant metastasis-free survival rates were 85.2% vs. 78.9% (P = 0.318), 71.6% vs. 71.0% (P = 0.847), 93.5% vs. 92.6% (P = 0.904), and 80.9% vs. 80.1% (P = 0.925) for the group treated every three weeks and weekly, respectively.Subgroup analyses indicated no significant differences in the survival rates of the two groups among patients with early- or advanced-stage disease.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong Province, People's Republic of China; Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, People's Republic of China.

ABSTRACT

Background: We aimed to compare the long-term survival outcomes and acute toxicity of cisplatin administered weekly versus every three weeks concurrently with intensity-modulated radiotherapy (IMRT) in patients with nasopharyngeal carcinoma (NPC).

Methods: This was a retrospective review of 154 patients with histologically proven, non-disseminated NPC who were treated using IMRT between January 2003 and December 2007. Seventy-three patients (47.4%) received 5-7 weeks of 30-40 mg/m2 cisplatin weekly; 81 patients (52.6%) received two or three cycles of 80 mg/m2 cisplatin every three weeks. IMRT was delivered at 68 Gy/30 fractions to the nasopharyngeal gross target volume and 60-66 Gy to the involved neck area.

Results: The clinical characteristics and treatment factors of the two groups were well-balanced. The median follow-up was 74 months (range, 6-123 months), and the 5-year overall survival, disease-free survival, locoregional relapse-free survival, and distant metastasis-free survival rates were 85.2% vs. 78.9% (P = 0.318), 71.6% vs. 71.0% (P = 0.847), 93.5% vs. 92.6% (P = 0.904), and 80.9% vs. 80.1% (P = 0.925) for the group treated every three weeks and weekly, respectively. Subgroup analyses indicated no significant differences in the survival rates of the two groups among patients with early- or advanced-stage disease. The incidence of acute toxicities was similar between groups.

Conclusion: IMRT with concurrent cisplatin administered weekly or every three weeks leads to similar long-term survival outcomes and acute toxicity in NPC regardless of whether patients have early- or advanced-stage disease.

Show MeSH

Related in: MedlinePlus

Survival curves for patients with NPC.(A) OS, (B) DFS, (C) LRRFS, and (D) DMFS. Hazard ratios (HRs) were calculated with an unadjusted Cox proportional hazards model; P-values were calculated with the unadjusted log-rank test.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4199726&req=5

pone-0110765-g001: Survival curves for patients with NPC.(A) OS, (B) DFS, (C) LRRFS, and (D) DMFS. Hazard ratios (HRs) were calculated with an unadjusted Cox proportional hazards model; P-values were calculated with the unadjusted log-rank test.

Mentions: The overall 5-year OS, DFS, LRRFS, and DMFS rates were 82.3%, 71.3%, 93.1%, and 80.5%, respectively. The 5-year OS, DFS, LRRFS, and DMFS rates were not significantly different between the two treatment groups (every three weeks vs. weekly: OS = 85.2% vs. 78.9%, P = 0.318; DFS = 71.6% vs. 71.0%, P = 0.847; LRRFS = 93.5% vs. 92.6%, P = 0.904; DMFS = 80.9% vs. 80.1%, P = 0.925; Fig. 1). The 5-year OS and DFS rates for patients with early- or advanced-stage disease in the two treatment groups were not significantly different (Fig. 2).


Comparison of long-term survival and toxicity of cisplatin delivered weekly versus every three weeks concurrently with intensity-modulated radiotherapy in nasopharyngeal carcinoma.

Tao CJ, Lin L, Zhou GQ, Tang LL, Chen L, Mao YP, Zeng MS, Kang TB, Jia WH, Shao JY, Mai HQ, Lin AH, Ma J, Sun Y - PLoS ONE (2014)

Survival curves for patients with NPC.(A) OS, (B) DFS, (C) LRRFS, and (D) DMFS. Hazard ratios (HRs) were calculated with an unadjusted Cox proportional hazards model; P-values were calculated with the unadjusted log-rank test.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4199726&req=5

pone-0110765-g001: Survival curves for patients with NPC.(A) OS, (B) DFS, (C) LRRFS, and (D) DMFS. Hazard ratios (HRs) were calculated with an unadjusted Cox proportional hazards model; P-values were calculated with the unadjusted log-rank test.
Mentions: The overall 5-year OS, DFS, LRRFS, and DMFS rates were 82.3%, 71.3%, 93.1%, and 80.5%, respectively. The 5-year OS, DFS, LRRFS, and DMFS rates were not significantly different between the two treatment groups (every three weeks vs. weekly: OS = 85.2% vs. 78.9%, P = 0.318; DFS = 71.6% vs. 71.0%, P = 0.847; LRRFS = 93.5% vs. 92.6%, P = 0.904; DMFS = 80.9% vs. 80.1%, P = 0.925; Fig. 1). The 5-year OS and DFS rates for patients with early- or advanced-stage disease in the two treatment groups were not significantly different (Fig. 2).

Bottom Line: The clinical characteristics and treatment factors of the two groups were well-balanced.The median follow-up was 74 months (range, 6-123 months), and the 5-year overall survival, disease-free survival, locoregional relapse-free survival, and distant metastasis-free survival rates were 85.2% vs. 78.9% (P = 0.318), 71.6% vs. 71.0% (P = 0.847), 93.5% vs. 92.6% (P = 0.904), and 80.9% vs. 80.1% (P = 0.925) for the group treated every three weeks and weekly, respectively.Subgroup analyses indicated no significant differences in the survival rates of the two groups among patients with early- or advanced-stage disease.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong Province, People's Republic of China; Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, People's Republic of China.

ABSTRACT

Background: We aimed to compare the long-term survival outcomes and acute toxicity of cisplatin administered weekly versus every three weeks concurrently with intensity-modulated radiotherapy (IMRT) in patients with nasopharyngeal carcinoma (NPC).

Methods: This was a retrospective review of 154 patients with histologically proven, non-disseminated NPC who were treated using IMRT between January 2003 and December 2007. Seventy-three patients (47.4%) received 5-7 weeks of 30-40 mg/m2 cisplatin weekly; 81 patients (52.6%) received two or three cycles of 80 mg/m2 cisplatin every three weeks. IMRT was delivered at 68 Gy/30 fractions to the nasopharyngeal gross target volume and 60-66 Gy to the involved neck area.

Results: The clinical characteristics and treatment factors of the two groups were well-balanced. The median follow-up was 74 months (range, 6-123 months), and the 5-year overall survival, disease-free survival, locoregional relapse-free survival, and distant metastasis-free survival rates were 85.2% vs. 78.9% (P = 0.318), 71.6% vs. 71.0% (P = 0.847), 93.5% vs. 92.6% (P = 0.904), and 80.9% vs. 80.1% (P = 0.925) for the group treated every three weeks and weekly, respectively. Subgroup analyses indicated no significant differences in the survival rates of the two groups among patients with early- or advanced-stage disease. The incidence of acute toxicities was similar between groups.

Conclusion: IMRT with concurrent cisplatin administered weekly or every three weeks leads to similar long-term survival outcomes and acute toxicity in NPC regardless of whether patients have early- or advanced-stage disease.

Show MeSH
Related in: MedlinePlus